Life Sciences & Healthcare
The Life Sciences & Healthcare industry group strives to support clients in addressing the challenges that impact today’s industry.
Unleash AI's potential
Measuring the return from pharmaceutical innovation
Our 14th annual report tracks the returns on R&D investment that the largest biopharma companies might expect to achieve from their late-stage pipelines. This analysis shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.
